Physician profile
Michael J Marcello
NPI 1366449167
$5,208.09
in general payments reported to CMS, 2019-2025
40 companies · $1,224 in 2025
The $1,224 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,102 · 2020: $355 · 2021: $838 · 2022: $375 · 2023: $208 · 2024: $1,105 · 2025: $1,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,537.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,097.00 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $702.63 | 2019-2025 | Farxiga |
| Amgen INC. | $434.69 | 2019-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $375.76 | 2019-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.63 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $252.21 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Ironwood Pharmaceuticals, INC | $216.30 | 2019-2020 | |
| Allergan, INC. | $198.97 | 2019-2020 | |
| Exact Sciences Corporation | $175.17 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $157.66 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $153.56 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $148.49 | 2019-2025 | Xifaxan, Trulance |
| Supernus Pharmaceuticals, INC. | $140.83 | 2024-2025 | Qelbree |
| Pfizer INC. | $106.40 | 2024-2025 | |
| Astellas Pharma US INC | $70.67 | 2024-2025 | Veozah |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $63.46 | 2024-2025 | |
| Amarin Pharma, INC. | $59.14 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $54.71 | 2024-2025 | Voquezna |
| Vanda Pharmaceuticals INC. | $47.87 | 2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $47.10 | 2019 | |
| Dexcom, INC. | $46.94 | 2024-2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.13 | 2025 | Caplyta |
| Novo Nordisk INC | $32.64 | 2024-2025 | Ozempic, Rybelsus |
| Ardelyx, INC. | $30.02 | 2025 | Ibsrela |
| Sunovion Pharmaceuticals INC. | $27.32 | 2019 | |
| Abiomed | $26.67 | 2023 | Impella |
| E.R. Squibb & Sons, L.L.C. | $21.48 | 2024 | Eliquis |
| Mylan Specialty L.P. | $21.28 | 2023 | Yupelri |
| Corium, LLC | $20.48 | 2025 | Azstarys |
| Verona Pharma, INC. | $20.00 | 2025 | Ohtuvayre |
| Alkermes, INC. | $19.11 | 2023 | Aristada, Lybalvi |
| Abbott Laboratories | $18.18 | 2024 | Freestyle Libre |
| Merck Sharp & Dohme LLC | $16.82 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $16.66 | 2019 | |
| Viatris Specialty LLC | $16.46 | 2025 | Yupelri |
| Tolmar, INC. | $15.68 | 2024 | |
| Genentech USA, INC. | $13.83 | 2019 | |
| Eisai INC. | $13.72 | 2021 | |
| Circassia INC. | $13.20 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Marcello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.